Switch theme
Sign up to access all valuation multiples
BridgeBio Pharma is a biotechnology company focused on discovering, developing, testing, and delivering transformative treatments for patients with genetic diseases. The company has four programs in its late-stage pipeline focusing on Mendelian disorders, oncology, and gene therapy. One of its key programs, Attruby (acoramidis) , is an orally administered small molecule designed to stabilize tetrameric transthyretin for the treatment of transthyretin amyloid cardiomyopathy.
2019
730
LTM Revenue $293M
LTM EBITDA -$507M
$7.8B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
BridgeBio Pharma has a last 12-month revenue (LTM) of $293M and a last 12-month EBITDA of -$507M.
In the most recent fiscal year, BridgeBio Pharma achieved revenue of $222M and an EBITDA of -$437M.
BridgeBio Pharma expects next 12-month revenue of XXX and NTM EBITDA of XXX
See BridgeBio Pharma valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $293M | XXX | $222M | XXX | XXX | XXX |
| Gross Profit | $282M | XXX | $218M | XXX | XXX | XXX |
| Gross Margin | 96% | XXX | 98% | XXX | XXX | XXX |
| EBITDA | -$507M | XXX | -$437M | XXX | XXX | XXX |
| EBITDA Margin | -173% | XXX | -197% | XXX | XXX | XXX |
| EBIT | -$564M | XXX | -$577M | XXX | XXX | XXX |
| EBIT Margin | -193% | XXX | -260% | XXX | XXX | XXX |
| Net Profit | -$574M | XXX | -$536M | XXX | XXX | XXX |
| Net Margin | -196% | XXX | -241% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $1.0B | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, BridgeBio Pharma's stock price is $34.
BridgeBio Pharma has current market cap of $6.5B, and EV of $7.8B.
See BridgeBio Pharma trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $7.8B | $6.5B | XXX | XXX | XXX | XXX | $-2.97 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, BridgeBio Pharma has market cap of $6.5B and EV of $7.8B.
BridgeBio Pharma's trades at 35.2x EV/Revenue multiple, and -17.9x EV/EBITDA.
Equity research analysts estimate BridgeBio Pharma's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
BridgeBio Pharma has a P/E ratio of -11.3x.
See valuation multiples for BridgeBio Pharma and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $6.5B | XXX | $6.5B | XXX | XXX | XXX |
| EV (current) | $7.8B | XXX | $7.8B | XXX | XXX | XXX |
| EV/Revenue | 26.7x | XXX | 35.2x | XXX | XXX | XXX |
| EV/EBITDA | -15.4x | XXX | -17.9x | XXX | XXX | XXX |
| EV/EBIT | -13.9x | XXX | -13.5x | XXX | XXX | XXX |
| EV/Gross Profit | 27.7x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.3x | XXX | -12.1x | XXX | XXX | XXX |
| EV/FCF | -21.0x | XXX | -14.8x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialBridgeBio Pharma's last 12 month revenue growth is 72%
BridgeBio Pharma's revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $1.1M for the same period.
BridgeBio Pharma's rule of 40 is -6006% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
BridgeBio Pharma's rule of X is 7% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for BridgeBio Pharma and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 72% | XXX | 73% | XXX | XXX | XXX |
| EBITDA Margin | -173% | XXX | -197% | XXX | XXX | XXX |
| EBITDA Growth | -25% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -6006% | XXX | -125% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 7% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $0.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.1M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 228% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 358% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
BridgeBio Pharma acquired XXX companies to date.
Last acquisition by BridgeBio Pharma was XXXXXXXX, XXXXX XXXXX XXXXXX . BridgeBio Pharma acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was BridgeBio Pharma founded? | BridgeBio Pharma was founded in 2019. |
| Where is BridgeBio Pharma headquartered? | BridgeBio Pharma is headquartered in United States of America. |
| How many employees does BridgeBio Pharma have? | As of today, BridgeBio Pharma has 730 employees. |
| Who is the CEO of BridgeBio Pharma? | BridgeBio Pharma's CEO is Dr. Neil Kumar, PhD. |
| Is BridgeBio Pharma publicy listed? | Yes, BridgeBio Pharma is a public company listed on NAS. |
| What is the stock symbol of BridgeBio Pharma? | BridgeBio Pharma trades under BBIO ticker. |
| When did BridgeBio Pharma go public? | BridgeBio Pharma went public in 2019. |
| Who are competitors of BridgeBio Pharma? | Similar companies to BridgeBio Pharma include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of BridgeBio Pharma? | BridgeBio Pharma's current market cap is $6.5B |
| What is the current revenue of BridgeBio Pharma? | BridgeBio Pharma's last 12 months revenue is $293M. |
| What is the current revenue growth of BridgeBio Pharma? | BridgeBio Pharma revenue growth (NTM/LTM) is 72%. |
| What is the current EV/Revenue multiple of BridgeBio Pharma? | Current revenue multiple of BridgeBio Pharma is 26.7x. |
| Is BridgeBio Pharma profitable? | Yes, BridgeBio Pharma is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of BridgeBio Pharma? | BridgeBio Pharma's last 12 months EBITDA is -$507M. |
| What is BridgeBio Pharma's EBITDA margin? | BridgeBio Pharma's last 12 months EBITDA margin is -173%. |
| What is the current EV/EBITDA multiple of BridgeBio Pharma? | Current EBITDA multiple of BridgeBio Pharma is -15.4x. |
| What is the current FCF of BridgeBio Pharma? | BridgeBio Pharma's last 12 months FCF is -$373M. |
| What is BridgeBio Pharma's FCF margin? | BridgeBio Pharma's last 12 months FCF margin is -127%. |
| What is the current EV/FCF multiple of BridgeBio Pharma? | Current FCF multiple of BridgeBio Pharma is -21.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
